Allergy

Intranasal epinephrine emerges as a promising, needle-free solution for treating severe allergic reactions, showing high effectiveness and usability in clinical settings.

Sublingual epinephrine film matches adult PK/PD in kids aged 7-17 with a history of allergic reactions and high risk for serious allergic reactions, incluing anaphylaxis.

Tezepelumab's approval marks the first for a TSLP-targeting biologic for CRSwNP, backed by WAYPOINT trial data showing sustained symptom and polyp reduction.

Corticosteroids following resolution of anaphylaxis should be chosen with clear, clinical rationale and reserved for select children, study authors concluded.

A single dose of neffy was effective in nearly 90% of patients treated for anaphylactic reactions during oral food challenge and allergen immunotherapy.

Clinical skepticism about the parity in effectiveness of epinephrine delivered via nasal spray vs autoinjector is rooted in fixed assumptions that bear examination, authors say.

Neffy, a needle-free epinephrine nasal spray, showed promise as a safe alternative for treating anaphylaxis in children with food allergies in a phase 3 trial.

The FDA assigned a Prescription Drug User Fee Act (PDUFA) target action date of January 31, 2026.

Nasus Pharma says promising phase 2 results for FMXIN002 show statistically significantly faster absorption than traditional autoinjectors and are published in global journal.

Your daily dose of the clinical news you may have missed.